TeamDrive
RUS

Russian authorities proposed to introduce liability for false drug prices

13 September 2017

GMP News

The Russian Ministry of Health proposed to introduce administrative liability for legal entities in case of false information provided during the state registration/re-registration of maximum selling prices for the medicines included in list of vital and essential drugs (VED).

Currently, the law does not stipulate any liability of legal entities (holders or owners of the registration certificate of medicinal product for human use, or party authorized by such holders or owners) for providing false information at the state registration (re-registration) of the manufacturer’s maximum selling prices for medicinal products included in the list of vital and essential drugs.

The draft federal law provides for amending the Russian Code of Administrative Offenses for submission of false information by the holder or owner of the registration certificate of medicinal product for human use (party authorized by such holders or owners) during the state registration (re-registration) of the manufacturer’s maximum selling prices for medicinal products included in the list of VED, changes to the register’s entry on the state registration of the manufacturer’s maximum selling price for medicinal product, which affected the results of economic analysis of the manufacturer’s maximum selling price of medicinal product for human use and led to unreasonable increase of the manufacturer’s maximum selling price for medicinal product.

According to the draft law, these offenses would entail the imposition of administrative fine on legal entities in the twofold the excess of the proceeds received from the sale of medicinal products as a result of unreasonable increase of the manufacturer’s maximum selling prices for medicinal products during the entire period in which the offense was committed, but no more than one year.

Source


Previous publication Next publication

Media Center

  • 25 September 2017

    Russian University creates a bank of biomolecules for new drugs

    The research activities of Genomic and Regenerative Medicine Center established at the School of Biomedicine in the Far Eastern Federal University (FEFU) will be based on unique natural resources of the Russian Far East. The scientists will study the biodiversity of the region, including marine organisms, create a bank of biomolecules for new drugs, and introduce innovative diagnostic and treatment methods into routine medical practice.

  • 25 September 2017

    Transition to multicomponent preventive drugs is necessary

    During the second BIOTECHMED conference held in Gelendzhik, the representatives of Nacimbio, a company which is part of Rostec Corporation, participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar.

  • 22 September 2017

    SPIC’s will ensure more predictability for pharmaceutical companies in Russia

    A meeting of the working group of the Coordination Council in the Area of Circulation of Medicines and Medical Devices held in the Russian Union of Industrialists and Entrepreneurs (RSPP) examined the state and development prospects of manufacturing the drugs for the treatment of oncological diseases in Russia.

  • 22 September 2017

    Cancer biobank Indivumed and CRO Helomics team up on precision medicine

    Indivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical datIndivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical data collected from patients around the world to help advance research in personalized cancer treatments. collected from patients around the world to help advance research in personalized cancer treatments.

Read more